Debt - Narrative (Details)		1 Months Ended					12 Months Ended			48 Months Ended
	Jan. 30, 2013 USD ($)	May 31, 2021 USD ($) shares	Feb. 28, 2019 USD ($) day $ / shares shares	Feb. 28, 2018 USD ($) $ / shares	Nov. 30, 2015 USD ($)	Jan. 31, 2013	Dec. 31, 2022 USD ($) day institution shares	Dec. 31, 2021 USD ($) institution shares	Dec. 31, 2020 USD ($)	Dec. 31, 2016 USD ($) shares	Jan. 01, 2022 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2019 USD ($)	Feb. 01, 2019 USD ($)
Debt Instrument [Line Items]
Converted debt amount							$ 0	$ 68,775,000	$ 0
Loss on conversion of the 2025 Notes							0	11,111,000	0
Equity							1,561,648,000	1,685,126,000	1,671,551,000				$ 1,614,759,000
Remaining principal							256,251,000	205,271,000
Credit line capacity							105,348,000
Goodwill							$ 595,851,000	$ 520,601,000			$ 710,408,000	$ 718,625,000
Number of financial institutions | institution							13	11
BioReference Laboratories, Inc.
Debt Instrument [Line Items]
Net assets							$ 608,600,000
Goodwill							283,000,000
Intangible assets							$ 187,900,000
OPKO Health Europe
Debt Instrument [Line Items]
Weighted average interest rate (as a percent)							1.90%	3.50%
Retained Earnings
Debt Instrument [Line Items]
Equity							$ (1,822,923,000)	$ (1,511,976,000)	(1,481,833,000)				(1,511,077,000)
Additional Paid-in Capital
Debt Instrument [Line Items]
Equity							$ 3,421,872,000	3,222,487,000	$ 3,152,694,000				3,142,993,000
Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Equity								(21,642,000)			21,600,000		(1,342,000)
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
Debt Instrument [Line Items]
Equity								17,458,000			17,500,000		$ (1,342,000)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
Debt Instrument [Line Items]
Equity								(39,100,000)			$ (39,100,000)
Minimum | OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates (as a percent)							0.70%
Maximum | OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates (as a percent)							4.50%
Convertible Debt
Debt Instrument [Line Items]
Interest rate of notes payable (as a percent)			4.50%
Senior Notes
Debt Instrument [Line Items]
Remaining principal							$ 142,096,000	119,360,000
Line of Credit
Debt Instrument [Line Items]
Remaining principal							$ 13,740,000	$ 13,672,000
Weighted average interest rate (as a percent)							5.50%	5.40%
Convertible Senior Notes Due 2025 | Convertible Debt
Debt Instrument [Line Items]
Debt face amount			$ 200,000,000
Conversion ratio			0.2367424
Conversion price (in dollars per share) | $ / shares			$ 4.22
Converted debt amount		$ 55,400,000
Shares issued on converted debt (in shares) | shares		19,051,270
Loss on conversion of the 2025 Notes								$ 11,100,000
Shares issuable under debt agreement (in shares) | shares			30,000,000
Decrease in shares issuable under debt agreement (in shares) | shares		8,105,175
Outstanding shares on converted debt (in shares) | shares							21,144,825	21,144,825
Proceeds one-time nominal fee							$ 300,000
Remaining principal							$ 142,096,000	$ 119,360,000
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period one
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)			130.00%
Equivalent redemption price (as a percent)			100.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period two
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)			98.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Redemption period three
Debt Instrument [Line Items]
Convertible debt, stock price trigger threshold (as a percent)							130.00%
Equivalent redemption price (as a percent)							100.00%
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period one
Debt Instrument [Line Items]
Number of trading days | day			20
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period two
Debt Instrument [Line Items]
Number of trading days | day			5
Convertible Senior Notes Due 2025 | Convertible Debt | Minimum | Redemption period three
Debt Instrument [Line Items]
Number of trading days | day							20
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period one
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day			30
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period two
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day			5
Convertible Senior Notes Due 2025 | Convertible Debt | Maximum | Redemption period three
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price | day							30
5% Convertible Notes | Convertible Debt
Debt Instrument [Line Items]
Debt face amount				$ 55,000,000
Interest rate of notes payable (as a percent)				5.00%
Conversion price (in dollars per share) | $ / shares				$ 5.00
Debt instrument, term				5 years
Minimum conversion notice (in days)				30 days
Maximum conversion notice (in days)				60 days
Remaining principal							$ 68,275,000	65,525,000
Notes Due February 1, 2033 | Convertible Debt
Debt Instrument [Line Items]
Converted debt amount										$ 143,200,000
Notes Due February 1, 2033 | Convertible Debt | Equity securities
Debt Instrument [Line Items]
Shares issued on converted debt (in shares) | shares										21,539,873
Notes Due February 1, 2033 | Senior Notes
Debt Instrument [Line Items]
Debt face amount	$ 175,000,000
Interest rate of notes payable (as a percent)	3.00%
Equivalent redemption price (as a percent)	100.00%
Notes Due February 1, 2033 | Notes
Debt Instrument [Line Items]
Equivalent redemption price (as a percent)						100.00%
Debt repurchase amount														$ 28,800,000
Remaining principal							3,050,000	3,050,000						$ 3,000,000
New Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining principal							18,080,000	0
Credit line capacity					$ 75,000,000
Remaining borrowing capacity							16,800,000
Long-term line of credit, noncurrent							$ 18,100,000	$ 0
New Credit Agreement | Line of Credit | Revolving Credit Facility | 50% Or More Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)					0.375%
New Credit Agreement | Line of Credit | Revolving Credit Facility | Less Than or Equal To 50% Of Revolving Commitment
Debt Instrument [Line Items]
Commitment fee (as a percent)					0.25%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)					2.50%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)					0.75%
New Credit Agreement | Line of Credit | Revolving Credit Facility | LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)					1.75%
New Credit Agreement | Line of Credit | Swingline
Debt Instrument [Line Items]
Credit line capacity					$ 20,000,000
New Credit Agreement | Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Credit line capacity					$ 20,000,000